Androgen Receptor Abnormalities in Castration-recurrent Prostate Cancer

Overview

Journal Expert Rev Endocrinol Metab

Specialty Endocrinology

Date 2010 Mar 16

PMID 20228873

Citations 18

Authors

Lucas P Nacusi

Donald J Tindall

Affiliations

Soon will be listed here.

Abstract

The androgen receptor (AR) plays a critical role in prostate cancer (PCa) development and progression. Despite the success of androgen-deprivation therapy, remission occurs in almost all cases. This stage of the disease is called castration-recurrent PCa (CRPC). CRPC cells adapt to low circulating levels of androgens, and active AR is maintained by numerous cellular mechanisms. Some mutations in the AR make it more responsive to lower androgen levels or other steroids. Furthermore, in this advance stage of the disease, PCa cells express the enzymes necessary for de novo synthesis of androgens. AR is also activated in a ligand-independent manner. Therefore, it is important to understand the mechanisms of AR activation and its deregulation during CRPC. The purpose of this article is to discuss mechanisms that are involved in modulation of AR activity and specificity.

Citing Articles

Reduction of Prostate Cancer Risk: Role of Frequent Ejaculation-Associated Mechanisms.

Hassan M, Flanagan T, Eshaq A, Altamimi O, Altalag H, Alsharif M Cancers (Basel). 2025; 17(5).

PMID: 40075690 PMC: 11898507. DOI: 10.3390/cancers17050843.

Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer.

Pandey M, Cuddihy G, Gordon J, Cox M, Wasan K Pharmaceutics. 2021; 13(9).

PMID: 34575583 PMC: 8467449. DOI: 10.3390/pharmaceutics13091509.

Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer.

Hillebrand A, Pizzolato L, Silva Neto B, Branchini G, Simoni Brum I PLoS One. 2018; 13(7):e0200613.

PMID: 30028845 PMC: 6054396. DOI: 10.1371/journal.pone.0200613.

Deletion of tumor suppressors adenomatous polyposis coli and Smad4 in murine luminal epithelial cells causes invasive prostate cancer and loss of androgen receptor expression.

Valkenburg K, De Marzo A, Williams B Oncotarget. 2017; 8(46):80265-80277.

PMID: 29113300 PMC: 5655195. DOI: 10.18632/oncotarget.17919.

Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.

Magani F, Peacock S, Rice M, Martinez M, Greene A, Magani P Mol Cancer Res. 2017; 15(11):1469-1480.

PMID: 28811363 PMC: 5770277. DOI: 10.1158/1541-7786.MCR-17-0280.

References

GROSSMANN M, Huang H, Tindall D . Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst. 2001; 93(22):1687-97. DOI: 10.1093/jnci/93.22.1687. View

Stanbrough M, Bubley G, Ross K, Golub T, Rubin M, Penning T . Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006; 66(5):2815-25. DOI: 10.1158/0008-5472.CAN-05-4000. View

Titus M, Schell M, Lih F, Tomer K, Mohler J . Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005; 11(13):4653-7. DOI: 10.1158/1078-0432.CCR-05-0525. View

Wu F, Mo Y . Ubiquitin-like protein modifications in prostate and breast cancer. Front Biosci. 2006; 12:700-11. DOI: 10.2741/2094. View

Wilson J . The role of 5alpha-reduction in steroid hormone physiology. Reprod Fertil Dev. 2002; 13(7-8):673-8. DOI: 10.1071/rd01074. View

Mukhopadhyay D, Dasso M . Modification in reverse: the SUMO proteases. Trends Biochem Sci. 2007; 32(6):286-95. DOI: 10.1016/j.tibs.2007.05.002. View

Lapouge G, Marcias G, Erdmann E, Kessler P, Cruchant M, Serra S . Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer. Adv Exp Med Biol. 2008; 617:529-34. DOI: 10.1007/978-0-387-69080-3_53. View

Callewaert L, Verrijdt G, Haelens A, Claessens F . Differential effect of small ubiquitin-like modifier (SUMO)-ylation of the androgen receptor in the control of cooperativity on selective versus canonical response elements. Mol Endocrinol. 2004; 18(6):1438-49. DOI: 10.1210/me.2003-0313. View

Moul J, Chodak G . Combination hormonal therapy: a reassessment within advanced prostate cancer. Prostate Cancer Prostatic Dis. 2004; 7 Suppl 1:S2-7. DOI: 10.1038/sj.pcan.4500741. View

10.

Levinson A, Nagler E, Lowe F . Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus. Urology. 2005; 65(1):91-4. DOI: 10.1016/j.urology.2004.08.053. View

11.

Scher H, Sawyers C . Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005; 23(32):8253-61. DOI: 10.1200/JCO.2005.03.4777. View

12.

Andriole G, Bruchovsky N, Chung L, Matsumoto A, Rittmaster R, Roehrborn C . Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004; 172(4 Pt 1):1399-403. DOI: 10.1097/01.ju.0000139539.94828.29. View

13.

Bain D, Heneghan A, Connaghan-Jones K, Miura M . Nuclear receptor structure: implications for function. Annu Rev Physiol. 2006; 69:201-20. DOI: 10.1146/annurev.physiol.69.031905.160308. View

14.

Debes J, Tindall D . Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004; 351(15):1488-90. DOI: 10.1056/NEJMp048178. View

15.

Smith D, Toft D . Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions. Mol Endocrinol. 2008; 22(10):2229-40. PMC: 2582531. DOI: 10.1210/me.2008-0089. View

16.

Culig Z, Bartsch G, Hobisch A . Antiandrogens in prostate cancer endocrine therapy. Curr Cancer Drug Targets. 2004; 4(5):455-61. DOI: 10.2174/1568009043332925. View

17.

Wright A, Thomas L, Douglas R, Lazier C, Rittmaster R . Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest. 1996; 98(11):2558-63. PMC: 507713. DOI: 10.1172/JCI119074. View

18.

Locke J, Guns E, Lubik A, Adomat H, Hendy S, Wood C . Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008; 68(15):6407-15. DOI: 10.1158/0008-5472.CAN-07-5997. View

19.

Cheng J, Bawa T, Lee P, Gong L, Yeh E . Role of desumoylation in the development of prostate cancer. Neoplasia. 2006; 8(8):667-76. PMC: 1601940. DOI: 10.1593/neo.06445. View

20.

Dehm S, Tindall D . Regulation of androgen receptor signaling in prostate cancer. Expert Rev Anticancer Ther. 2005; 5(1):63-74. DOI: 10.1586/14737140.5.1.63. View